Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
| ▸ | DPP4 | P27487 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.70 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.70 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.70 |
| ▸ | GAPDH | P04406 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | STAT6 | P42226 | 1/20 | 0.70 |
| ▸ | PI4KA | P42356 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.70 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.70 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.70 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554813 | 1.00 | ADORA1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL7067739 | 1.00 | ADORA1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL6246363 | 0.88 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL7732691 | 0.87 | TYMP (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8610903 | 0.87 | ADORA1 (0.82) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8610899 | 0.87 | ADORA1 (0.82) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL31484253 | 0.87 | ADORA1 (0.82) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL10997946 | 0.86 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL12963362 | 0.86 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2040670 | 0.86 | ADORA1 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027363-B1 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2003-06-04 | — | — | EP | claimed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | claimed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | claimed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | claimed |
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387596-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024113009-A1 | AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-06-06 | — | — | WO | disclosed |
| WO-2016014846-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF INTRABODIES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| EP-1248632-A2 | COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2002-10-16 | — | — | EP | disclosed |
| EP-1239878-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6407076-B1 | ANTIISCHEMIC, ANTILIPOLYTIC, ANTICONVULSANT AND HYPOTENSIVE AGENTS; CARDIOVASCULAR AND NERVOUS SYSTEM DISORDERS; ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION | 2002-06-18 | — | — | US | disclosed |
| WO-2001045682-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045715-A2 | COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| EP-1027363-A2 | ADENOSINE A1-RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999024450-A2 | ADENSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 1999-05-20 | — | — | WO | disclosed |